Advances In™ Hematology: Translating Recent Evidence into the Treatment of Myelodysplastic Syndromes

Advances In™ Hematology: Translating Recent Evidence into the Treatment of Myelodysplastic Syndromes is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This educational activity is directed toward medical oncologists and hematologists who treat patients with myelodysplastic syndromes. Nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment of MDS will be invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
The correct diagnosis and classification of myelodysplastic syndrome (MDS) subtype is an important component to determining best therapeutic options for each patient. Risk stratification systems allow clinicians to categorize patient risk level and further determine best therapeutic options for patients with MDS. As data continue to be collected and reported from many trials, it is paramount that healthcare providers are kept up-to-date on forthcoming treatment options and recruiting trials that may be the best therapeutic option for patients. Recent reports from clinical trial data offer potential for changes to treatment paradigms for patients with MDS that need to be incorporated into the treatment decision-making process, as well as the into strategies for management of anemia and low platelet count.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the current categorization of MDS disease and how risk stratification impacts clinical decision-making
• Summarize evidence-based diagnostic and therapeutic strategies for the treatment of MDS
• Assess how individual patient characteristics can impact outcomes in MDS, including response to therapies, survival, or progression to AML
• Define the role of new and emerging therapies and their clinical applications to the future of MDS management.